{"hands_on_practices": [{"introduction": "The first step in managing allergic rhinitis is accurate diagnosis, which hinges on distinguishing it from its most common mimic: viral rhinitis. This exercise challenges you to move beyond symptom checklists and apply your knowledge of core immunopathology. By constructing the expected clinical trajectories from first principles, you will solidify your ability to interpret a patient's history and physical findings to make a confident differential diagnosis [@problem_id:5000819].", "problem": "An adult patient prospectively logs nasal symptoms, oral temperature, and endoscopic turbinate appearance twice daily over a $10$-day interval. You are asked to differentiate allergic rhinitis from viral rhinitis by reasoning from core immunopathophysiology to construct expected temporal trajectories of symptoms, fever association, and mucosal color changes across this $10$-day course, and then matching them to the options below.\n\nFundamental base to use for your construction:\n- Type I immediate hypersensitivity mediated by Immunoglobulin E (IgE) on mast cells produces an immediate phase within minutes of allergen re-exposure and a late phase after several hours, with predominant effects on nasal mucosal vascular permeability, glandular secretion, and sensory nerve irritation; in the absence of systemic pyrogenic cytokines, fever is not expected.\n- Viral upper respiratory infection elicits an innate immune response with endogenous pyrogens that can raise hypothalamic set-point temperature and produces hyperemia of infected mucosa; symptoms tend to peak early and resolve spontaneously over approximately $7$–$10$ days and are not strictly time-locked to discrete allergen exposures.\n\nWhich single option most consistently represents allergic rhinitis rather than viral rhinitis over this $10$-day interval?\n\nA. Day $1$ onset within $15$ minutes of cutting grass outdoors, with paroxysmal sneezing, nasal and ocular itch, and profuse watery rhinorrhea; similar flares recur within minutes of each daily outdoor exposure and a second wave of congestion occurs approximately $6$ hours after each exposure; oral temperatures remain between $36.5^\\circ \\mathrm{C}$ and $37.3^\\circ \\mathrm{C}$ on all $10$ days; nasal endoscopy on days $1$, $3$, and $7$ shows pale, edematous, slightly violaceous inferior turbinates without mucosal erythema; symptoms persist throughout the $10$ days while daily exposures continue.\n\nB. Gradual onset over days $0$–$2$ after a sick household contact, with scratchy throat then nasal congestion; oral temperature peaks at $38.3^\\circ \\mathrm{C}$ on days $1$–$2$ with chills and malaise; nasal mucosa appears diffusely erythematous and hyperemic on days $1$–$3$; watery rhinorrhea transitions to thicker mucoid discharge by days $4$–$5$; symptoms peak on day $3$ and improve steadily, resolving by day $9$ without relation to allergen exposure.\n\nC. No clear exposure trigger; insidious onset over day $1$ with progressive nasal congestion and rhinorrhea; oral temperatures remain $36.7^\\circ \\mathrm{C}$–$37.4^\\circ \\mathrm{C}$ throughout; nasal mucosa is beefy red and hyperemic on days $2$–$3$; symptoms peak on day $3$, discharge thickens by day $4$, and the course resolves by day $8$.\n\nD. Daily morning-dominant congestion and sneezing for $6$ days after a coworker developed a cold; a single fever spike to $38.0^\\circ \\mathrm{C}$ occurs on day $2$ with myalgias; nasal endoscopy on day $2$ shows erythematous, engorged turbinates; symptoms remit by day $7$ without clear relation to discrete environmental exposures.\n\nSelect one option.", "solution": "The problem statement is subjected to validation prior to deriving a solution.\n\n**Problem Validation**\n\n1.  **Givens Extraction**:\n    *   Patient logs symptoms, temperature, and endoscopic appearance twice daily for a $10$-day interval.\n    *   Task is to differentiate allergic rhinitis (AR) from viral rhinitis (VR) by constructing expected temporal trajectories based on core immunopathophysiology.\n    *   **Fundamental Principle 1 (Allergic Rhinitis)**: Type I immediate hypersensitivity is mediated by Immunoglobulin E (IgE) on mast cells. It produces an immediate phase (minutes after allergen re-exposure) and a late phase (several hours after). Effects include increased vascular permeability, glandular secretion, and sensory nerve irritation. Fever is not expected due to the absence of systemic pyrogenic cytokines.\n    *   **Fundamental Principle 2 (Viral Rhinitis)**: Viral infection elicits an innate immune response with endogenous pyrogens, which can cause fever. It produces hyperemia of infected mucosa. Symptoms peak early and resolve spontaneously over approximately $7$–$10$ days and are not time-locked to discrete allergen exposures.\n    *   The question asks for the single option most consistently representing allergic rhinitis.\n\n2.  **Validation Verdict**:\n    The problem is **valid**. It is scientifically grounded in established principles of immunology and clinical medicine. The premises accurately describe the pathophysiology of allergic and viral rhinitis. The problem is well-posed, objective, and contains sufficient information to allow for a logical deduction of the correct answer from the provided options. It does not violate any of the criteria for invalidity.\n\n**Solution Derivation**\n\nBased on the provided fundamental principles, we can construct the expected clinical profile for allergic rhinitis over a $10$-day period.\n\n*   **Pathophysiology and Timing**: Allergic rhinitis is triggered by re-exposure to a specific allergen. The IgE-mediated mast cell degranulation causes an \"immediate phase\" within minutes, characterized by sensory nerve irritation (leading to paroxysmal sneezing and itching) and increased vascular permeability and glandular secretion (leading to profuse, watery rhinorrhea). This is followed by a \"late phase\" several hours later, driven by cellular infiltration, which predominantly causes sustained nasal congestion. The entire cycle is contingent on allergen exposure.\n*   **Systemic Signs**: The process is localized and does not typically involve the systemic release of \"endogenous pyrogens.\" Therefore, fever is \"not expected.\" Body temperature should remain within the normal physiological range (approximately $36.5^\\circ \\mathrm{C}$ to $37.5^\\circ \\mathrm{C}$).\n*   **Mucosal Appearance**: The pathophysiology points to increased vascular permeability (edema) and venous engorgement. This results in turbinates that are typically described as pale, boggy, edematous, and potentially bluish or violaceous. This is in direct contrast to the \"hyperemia\" (active redness from arteriolar dilation) characteristic of viral infection.\n*   **Clinical Course**: The symptoms are directly linked to allergen exposure. If exposure is intermittent or daily, symptoms will recur in a predictable pattern (immediate and late phases) following each exposure and will persist as long as the exposure continues.\n\nWe will now evaluate each option against this constructed profile of allergic rhinitis.\n\n**Option-by-Option Analysis**\n\n**A. Day $1$ onset within $15$ minutes of cutting grass outdoors, with paroxysmal sneezing, nasal and ocular itch, and profuse watery rhinorrhea; similar flares recur within minutes of each daily outdoor exposure and a second wave of congestion occurs approximately $6$ hours after each exposure; oral temperatures remain between $36.5^\\circ \\mathrm{C}$ and $37.3^\\circ \\mathrm{C}$ on all $10$ days; nasal endoscopy on days $1$, $3$, and $7$ shows pale, edematous, slightly violaceous inferior turbinates without mucosal erythema; symptoms persist throughout the $10$ days while daily exposures continue.**\n\n*   **Trigger and Timing**: The onset is within $15$ minutes of a classic allergen exposure (cutting grass), consistent with the immediate phase. The recurrence of flares with each daily exposure is a hallmark of AR.\n*   **Symptom Phases**: The description of initial sneezing, itching, and watery rhinorrhea (immediate phase) followed by a wave of congestion $6$ hours later (late phase) perfectly matches the provided pathophysiology.\n*   **Fever**: The temperature range of $36.5^\\circ \\mathrm{C}$ to $37.3^\\circ \\mathrm{C}$ is afebrile, as expected for AR.\n*   **Mucosal Appearance**: \"pale, edematous, slightly violaceous inferior turbinates\" is the classic endoscopic finding for AR and contrasts with the hyperemia of viral infection.\n*   **Course**: The persistence of symptoms with ongoing exposure is characteristic of AR.\n*   **Verdict**: **Correct**. This option provides a textbook presentation of allergic rhinitis, consistent with every element of the provided fundamental principles.\n\n**B. Gradual onset over days $0$–$2$ after a sick household contact, with scratchy throat then nasal congestion; oral temperature peaks at $38.3^\\circ \\mathrm{C}$ on days $1$–$2$ with chills and malaise; nasal mucosa appears diffusely erythematous and hyperemic on days $1$–$3$; watery rhinorrhea transitions to thicker mucoid discharge by days $4$–$5$; symptoms peak on day $3$ and improve steadily, resolving by day $9$ without relation to allergen exposure.**\n\n*   **Trigger**: A sick household contact and gradual onset suggest an infectious etiology (viral rhinitis).\n*   **Fever**: The peak temperature of $38.3^\\circ \\mathrm{C}$ indicates fever, which is characteristic of viral infection but not AR.\n*   **Mucosal Appearance**: The mucosa is \"diffusely erythematous and hyperemic,\" which is the expected finding in viral rhinitis, not AR.\n*   **Course**: The self-limited course of $9$ days with changing discharge characteristics (\"thicker mucoid discharge\") is typical for a viral upper respiratory infection.\n*   **Verdict**: **Incorrect**. This scenario is a classic representation of viral rhinitis.\n\n**C. No clear exposure trigger; insidious onset over day $1$ with progressive nasal congestion and rhinorrhea; oral temperatures remain $36.7^\\circ \\mathrm{C}$–$37.4^\\circ \\mathrm{C}$ throughout; nasal mucosa is beefy red and hyperemic on days $2$–$3$; symptoms peak on day $3$, discharge thickens by day $4$, and the course resolves by day $8$.**\n\n*   **Trigger**: \"No clear exposure trigger\" and \"insidious onset\" are more typical of an infection than a discrete allergic reaction.\n*   **Mucosal Appearance**: The \"beefy red and hyperemic\" mucosa is a definitive sign of the inflammatory response seen in viral infections (hyperemia), not the pale edema of AR.\n*   **Course**: The self-limited course ($8$ days) with peaking symptoms and thickening discharge is characteristic of viral rhinitis. Although the patient is afebrile, the mucosal appearance and overall course are not consistent with AR.\n*   **Verdict**: **Incorrect**. This describes an afebrile viral rhinitis, not allergic rhinitis.\n\n**D. Daily morning-dominant congestion and sneezing for $6$ days after a coworker developed a cold; a single fever spike to $38.0^\\circ \\mathrm{C}$ occurs on day $2$ with myalgias; nasal endoscopy on day $2$ shows erythematous, engorged turbinates; symptoms remit by day $7$ without clear relation to discrete environmental exposures.**\n\n*   **Trigger**: Known sick contact (\"coworker developed a cold\") suggests an infectious cause.\n*   **Fever**: The fever spike to $38.0^\\circ \\mathrm{C}$ and associated myalgias are systemic signs of a viral infection.\n*   **Mucosal Appearance**: \"erythematous, engorged turbinates\" indicate hyperemia, which is characteristic of viral rhinitis.\n*   **Course**: The self-limited course ($7$ days) is typical for viral rhinitis.\n*   **Verdict**: **Incorrect**. This scenario clearly depicts a viral rhinitis.", "answer": "$$\\boxed{A}$$", "id": "5000819"}, {"introduction": "Diagnostic testing is not a simple binary process; its true power lies in its ability to modify our clinical suspicion. This problem provides a hands-on application of Bayes' theorem, a cornerstone of evidence-based medicine, to a common allergic rhinitis scenario. Completing this exercise will train you to quantitatively update your pre-test probability based on a diagnostic test result, providing a more precise and defensible estimate of the likelihood of disease [@problem_id:5000788].", "problem": "A patient with perennial nasal obstruction, rhinorrhea, and pruritus undergoes evaluation for allergic rhinitis in an otorhinolaryngology clinic. The clinical picture, seasonality, and household exposure profile lead the clinician to estimate a moderate pretest probability for clinically relevant sensitization to dust mite (Dermatophagoides species) of $p_0 = 0.40$. Serum specific immunoglobulin E (sIgE) to dust mite measured by a validated ImmunoCAP assay returns $2.0$ kilounits of allergen per liter (kUA/L). Clinically relevant sensitization is defined as immunoglobulin E-mediated reactivity that is associated with nasal symptoms and confirmed by a standardized reference (e.g., nasal allergen provocation test), and the diagnostic performance of the dichotomized test at the decision threshold $x \\geq 2.0$ kUA/L is characterized by sensitivity $S_e = 0.70$ and specificity $S_p = 0.90$ against the reference standard, based on pooled data from high-quality studies.\n\nUsing a principled probabilistic update from pretest to post-test probability grounded in established statistical inference for diagnostic tests, compute the post-test probability of clinically relevant dust mite sensitization for this patient given the observed sIgE result of $2.0$ kUA/L. Express your final answer as a decimal fraction and round to four significant figures.", "solution": "The problem requires the computation of the post-test probability of a medical condition given a pretest probability and the result of a diagnostic test with known performance characteristics. This is a direct application of Bayes' theorem, a fundamental principle of statistical inference.\n\nFirst, we must formalize the events and probabilities provided in the problem statement.\nLet $D$ represent the event that the patient has clinically relevant dust mite sensitization.\nLet $\\neg D$ represent the complementary event that the patient does not have clinically relevant dust mite sensitization.\nLet $T^+$ represent the event of a positive test result, which corresponds to a serum specific immunoglobulin E (sIgE) level $x \\geq 2.0 \\, \\text{kUA/L}$.\nLet $T^-$ represent the event of a negative test result, which corresponds to $x  2.0 \\, \\text{kUA/L}$.\n\nThe givens from the problem statement are translated into probabilistic terms as follows:\n1.  The pretest probability of the condition is the prior probability of event $D$:\n    $$P(D) = p_0 = 0.40$$\n2.  The probability of not having the condition is the complement:\n    $$P(\\neg D) = 1 - P(D) = 1 - 0.40 = 0.60$$\n3.  The sensitivity of the test, $S_e$, is the probability of a positive test result given that the patient has the condition:\n    $$S_e = P(T^+ | D) = 0.70$$\n4.  The specificity of the test, $S_p$, is the probability of a negative test result given that the patient does not have the condition:\n    $$S_p = P(T^- | \\neg D) = 0.90$$\n\nThe observed test result for the patient is an sIgE level of $2.0 \\, \\text{kUA/L}$, which satisfies the criterion for a positive test ($x \\geq 2.0 \\, \\text{kUA/L}$). Therefore, we are given the event $T^+$. The objective is to calculate the post-test probability of the condition, which is the conditional probability $P(D | T^+)$.\n\nBayes' theorem provides the formal relationship for this update:\n$$P(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+)}$$\nThe term $P(T^+ | D)$ is the sensitivity, and $P(D)$ is the pretest probability. Both are given. The denominator, $P(T^+)$, is the total probability of a positive test result. It can be calculated using the law of total probability, marginalizing over the disease state:\n$$P(T^+) = P(T^+ | D) P(D) + P(T^+ | \\neg D) P(\\neg D)$$\nThe term $P(T^+ | \\neg D)$ is the probability of a positive test in a patient without the condition, also known as the false positive rate. It can be derived from the specificity:\n$$P(T^+ | \\neg D) = 1 - P(T^- | \\neg D) = 1 - S_p = 1 - 0.90 = 0.10$$\nNow we can compute the total probability $P(T^+)$:\n$$P(T^+) = (0.70)(0.40) + (0.10)(0.60)$$\n$$P(T^+) = 0.28 + 0.06 = 0.34$$\nThis value represents the overall probability of any patient from this population (with a prevalence of $0.40$) testing positive.\n\nWith all components available, we can now compute the post-test probability $P(D | T^+)$:\n$$P(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+)} = \\frac{(0.70)(0.40)}{0.34}$$\n$$P(D | T^+) = \\frac{0.28}{0.34}$$\nThe fraction simplifies to $\\frac{28}{34} = \\frac{14}{17}$. To provide the answer as a decimal fraction, we perform the division:\n$$P(D | T^+) = \\frac{14}{17} \\approx 0.82352941176...$$\nThe problem requires the final answer to be rounded to four significant figures. The first four significant figures are $8$, $2$, $3$, and $5$. The fifth significant figure is $2$, which is less than $5$, so we round down (i.e., we truncate).\nTherefore, the post-test probability of clinically relevant dust mite sensitization is approximately $0.8235$.", "answer": "$$\\boxed{0.8235}$$", "id": "5000788"}, {"introduction": "Managing polysensitized patients represents a significant clinical challenge, where a 'treat-all' approach is often ineffective and ill-advised. This exercise introduces the power of Component-Resolved Diagnostics (CRD) to dissect complex sensitization patterns and identify the true drivers of a patient's allergic disease. By integrating detailed serological data with the clinical and exposure history, you will practice the high-level skill of prioritizing targets for allergen immunotherapy, paving the way for personalized and effective treatment [@problem_id:5000831].", "problem": "A $28$-year-old individual living in Stockholm presents with perennial nasal congestion and seasonal exacerbations characterized by sneezing, rhinorrhea, and itchy eyes. Symptom diaries document peak severity in April–May and again in June–July, with minimal symptoms in late summer–autumn. The patient keeps a female Labrador Retriever, has no cat exposure, and works in a sealed office building with mechanical ventilation. There is no reported dampness or mold. Skin-prick testing is positive to birch pollen, grass mix, weakly positive to ragweed, and variably positive to dog dander; dust mite and cat are borderline. Total immunoglobulin E (IgE) is $185\\,\\mathrm{kU/L}$. Component-Resolved Diagnostics (CRD) by fluorescence enzyme immunoassay yields:\n- Bet v $1$: $32\\,\\mathrm{kU/L}$; Bet v $2$ (profilin): $6\\,\\mathrm{kU/L}$; Bet v $4$ (polcalcin): $0.35\\,\\mathrm{kU/L}$\n- Phl p $1$: $22\\,\\mathrm{kU/L}$; Phl p $5$: $18\\,\\mathrm{kU/L}$\n- Amb a $1$: $4\\,\\mathrm{kU/L}$\n- Der p $1$: $0.7\\,\\mathrm{kU/L}$; Der p $2$: $0.5\\,\\mathrm{kU/L}$\n- Fel d $1$: $0.8\\,\\mathrm{kU/L}$\n- Can f $1$: $0.3\\,\\mathrm{kU/L}$; Can f $5$: $12\\,\\mathrm{kU/L}$\n- Immunoglobulin E to cross-reactive carbohydrate determinants (CCD): $0.35\\,\\mathrm{kU/L}$\n\nRegional aerobiology reports average seasonal airborne pollen counts of birch at approximately $200$ grains per $\\mathrm{m}^3$ in April–May and multi-species grass at approximately $150$ grains per $\\mathrm{m}^3$ in June–July; ragweed counts are typically $10$ grains per $\\mathrm{m}^3$ and sporadic. The patient reports oral pruritus with raw apple, hazelnut, and carrot; there are no lower airway symptoms.\n\nUsing the following foundational principles:\n- Type I hypersensitivity is mediated by allergen-specific immunoglobulin E (IgE) bound to high-affinity Fc epsilon receptor I (Fc$\\varepsilon$RI) on mast cells and basophils; clinical relevance of a sensitization depends on the presence of genuine sensitization to major, disease-driving components and sufficient exposure to that allergen.\n- Component-Resolved Diagnostics (CRD) distinguishes genuine sensitizers (e.g., birch Bet v $1$; timothy grass Phl p $1$/$5$; ragweed Amb a $1$; house dust mite Der p $1$/$2$; cat Fel d $1$; dog Can f $1$/$5$) from cross-reactive pan-allergens (e.g., profilins such as Bet v $2$; polcalcins such as Bet v $4$), which often lead to broad serological positivity but limited clinical relevance for allergen immunotherapy.\n- Allergen Immunotherapy (AIT) efficacy depends on targeting the clinically most relevant allergens with major components that are present in standardized extracts, in the context of meaningful, ongoing exposure. In European practice, prioritization typically limits simultaneous targets to at most $1$–$2$ allergens with high exposure relevance.\n- Dog allergen Can f $5$ (prostatic kallikrein) is largely confined to male dogs; exposure is negligible with female-only dog contact.\n\nWhich of the following is the most appropriate prioritization strategy for initiating allergen immunotherapy to reduce this patient’s allergic rhinitis burden?\n\nA. Initiate Allergen Immunotherapy (AIT) with standardized birch (Betula) pollen extract and timothy grass (Phleum pratense) pollen extract as the primary targets, and defer ragweed, dog, dust mite, and cat from AIT given low exposure or low clinical relevance; manage profilin-related oral allergy syndrome conservatively.\n\nB. Initiate AIT to profilin and polcalcin pan-allergens to achieve broad cross-protection across multiple plant families, and add ragweed extract because Amb a $1$ is detectable.\n\nC. Prepare a single Subcutaneous Immunotherapy (SCIT) vial mixing all positive allergens (birch, grass, ragweed, dust mite, cat, dog) to comprehensively address polysensitization, as broader coverage increases efficacy in polysensitized patients.\n\nD. Prioritize ragweed AIT due to Amb a $1$ positivity to prevent future clinical ragweed disease despite currently low regional ragweed exposure; add dog AIT targeting Can f $5$ because of the high specific IgE level.\n\nE. Initiate dog AIT focused on Can f $5$ because the specific IgE is high, and birch and grass can be deferred since pollen seasons are short and antihistamines are available.\n\nSelect the single best option that adheres to the stated principles and the patient’s exposure context.", "solution": "The task is to determine the most appropriate Allergen Immunotherapy (AIT) strategy by integrating the patient's clinical presentation, exposure history, and diagnostic test results with the provided foundational principles.\n\n1.  **Identify Clinically Relevant Sensitizations:**\n    *   **Birch Pollen:** The patient's severe symptoms in April–May directly correlate with the high birch pollen counts in Stockholm. The Component-Resolved Diagnostics (CRD) confirm a strong, genuine sensitization, with a very high level of specific IgE to the major birch allergen Bet v 1 ($32\\,\\mathrm{kU/L}$). This establishes birch as a primary driver of the patient's rhinitis.\n    *   **Grass Pollen:** The second symptom peak in June–July corresponds to the grass pollen season. The CRD shows high levels of specific IgE to the major grass group 1 and 5 allergens, Phl p 1 ($22\\,\\mathrm{kU/L}$) and Phl p 5 ($18\\,\\mathrm{kU/L}$), confirming a genuine and clinically significant grass pollen sensitization.\n    *   **Profilin Sensitization:** The presence of IgE to Bet v 2 ($6\\,\\mathrm{kU/L}$), a profilin pan-allergen, explains the patient's oral allergy syndrome with fruits and vegetables. As per Principle 2, this is a marker of cross-reactivity and not a primary target for AIT for respiratory symptoms.\n\n2.  **Evaluate Other Sensitizations for Clinical Relevance:**\n    *   **Dog Dander:** The patient has a high level of IgE to Can f 5 ($12\\,\\mathrm{kU/L}$). However, Principle 4 states that Can f 5 is a prostatic kallikrein specific to male dogs. Since the patient lives with a female dog, there is no exposure to this allergen, rendering the sensitization clinically irrelevant. Sensitization to the major dog allergen Can f 1 is negative ($0.35\\,\\mathrm{kU/L}$).\n    *   **Ragweed Pollen:** While there is low-level sensitization to the major ragweed allergen Amb a 1 ($4\\,\\mathrm{kU/L}$), regional aerobiology reports negligible exposure. According to Principle 1, a lack of exposure means this sensitization is not a current cause of symptoms.\n    *   **Dust Mite and Cat:** IgE levels to major dust mite (Der p 1, Der p 2) and cat (Fel d 1) allergens are very low/borderline, and cat exposure is absent. These are not clinically significant drivers.\n\n3.  **Formulate AIT Strategy:**\n    *   According to Principle 3, AIT should target the clinically most relevant allergens. The analysis definitively points to birch and grass pollen as the causes of the patient's most significant symptoms.\n    *   European practice guidelines (mentioned in Principle 3) recommend prioritizing and limiting AIT to one or two key allergens for which there is both genuine sensitization and significant exposure.\n    *   Therefore, the most logical and evidence-based strategy is to initiate AIT with extracts for birch pollen and grass pollen. All other sensitizations are either clinically irrelevant due to lack of exposure (dog, ragweed, cat) or of minor significance (dust mite).\n\n4.  **Evaluate Options:**\n    *   **Option A** aligns perfectly with this analysis. It targets birch and grass, defers the others for valid reasons, and correctly identifies the management for OAS.\n    *   **Option B** is incorrect as AIT is not targeted at pan-allergens like profilin for respiratory disease.\n    *   **Option C** is incorrect because mixing multiple allergens, especially clinically irrelevant ones, is inefficient and counter to modern AIT principles.\n    *   **Option D** is incorrect as it prioritizes allergens that are not causing the patient's current symptoms.\n    *   **Option E** is incorrect as it focuses on a clinically irrelevant sensitization (Can f 5) and inappropriately defers treatment for the main disease drivers.", "answer": "$$\\boxed{A}$$", "id": "5000831"}]}